glp 1 agonist moa Mechanism of action of GLP-1 agonists – My Endo Consult GLP-1 and the kidney: from
Description
In 2022, citing shortages of the drugs, the FDA allowed compounding pharmacies to make them but with the shortages over, the FDA stopped allowing compounding pharmacies to make tirzepatide (Mounjaro and Zepbound) in March, and semaglutide (Ozempic and Wegovy) last week
vTv Therapeutics Inc
Tirzepatide (Mounjaro, Zepbound) activates two: GLP-1 and GIP
Physiol Rev 97:721766
All research compounds referenced are intended for laboratory and research use only
The drugs are part of a broader class of medicine known as GLP-1s that have grown wildly popular for everything from type 2 diabetes to weight loss and are increasingly seen as having potential benefits far beyond those two conditions
